China's latest version of hepatitis B prevention guide for the first time included in the "optimized treatment" strategy

The 2010 edition of the “Guidelines for the Prevention and Treatment of Chronic Hepatitis B” was released in Beijing on the 10th, for the first time, the optimization of treatment strategies was included.

“This will play an important role in improving patient compliance, preventing drug resistance, shortening treatment duration, improving curative effect, and reducing medical costs.” Professor Zhuang Hui of the Chinese Academy of Engineering pointed out that the optimization of treatment strategies can be summarized as follows: The patient is selected according to the condition of the patient, and the medication is adjusted according to the monitoring situation during the treatment process, and if the occurrence of drug resistance occurs, the treatment plan is adjusted in time.

Wang Minbin, Director of Department of Infectious Diseases at Shanghai Changhai Hospital, Second Military Medical University, said: “An important point in optimizing treatment strategies is to optimize drugs, that is, to select drugs based on the level of the virus before treatment and the response of the patient for half a year.” Such as Lamy If the virus turns negative after six months of treatment, it can continue to be adhered to; if the virus does not turn negative, the dressing should be promptly changed or combined with adefovir dipivoxil to improve the therapeutic effect.

After China's first "Guide to the Prevention and Treatment of Chronic Hepatitis B" was issued, "antiviral therapy" was gradually accepted and widely recognized in the clinical setting of hepatitis B. However, the current status of hepatitis B treatment in China is still not optimistic, about 90% of patients do not have antiviral treatment, there is a large part of the patients themselves to stop the drug or change drugs, the economic burden is one of the factors.

According to the survey, 80% of hepatitis B patients in China have a monthly income of less than 3,000 yuan, and self- paid patients account for more than 50%, especially in rural areas. "If you do not fully consider the patient's affordability, the treatment of some patients will be difficult to adhere to and regulate." Wan Wei Bin pointed out that based on such national conditions, hepatitis B optimization treatment should follow the principle of efficacy, safety, and cost trinity.